| abstract |
Provided are ROR1 binding molecules, eg, variable heavy chain (VH) regions, anti-ROR1 antibodies comprising antibody fragments such as single chain fragments, and chimeric receptors comprising antibodies, eg, chimeric antigen receptors (CAR). In some embodiments, the antibody specifically binds to ROR1. Antibodies include human antibodies, such as those that compete with a reference antibody, such as a non-human reference antibody, for binding to ROR1. Also provided are genetically modified cells that express the chimeric receptor, and use of the binding molecules and cells in adoptive cell therapy. |